What is Jasper Therapeutics Earnings Power Value (EPV)?
As of Mar24, Jasper Therapeutics's earnings power value is $8.69. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Jasper Therapeutics Earnings Power Value (EPV) Historical Data
The historical data trend for Jasper Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jasper Therapeutics Earnings Power Value (EPV) Chart
|
Jasper Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
|
Jasper Therapeutics Quarterly Data
|
|
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Jasper Therapeutics's Earnings Power Value (EPV)
For the Biotechnology subindustry, Jasper Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jasper Therapeutics's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Jasper Therapeutics's Earnings Power Value (EPV) falls into.
Jasper Therapeutics Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Jasper Therapeutics (Jasper Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Executives
| Thomas G Wiggans |
director |
|
| William Lis |
director |
PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Jeetinder Singh Mahal |
officer: Chief Operating Officer |
C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065 |
| Ron Martell |
director, officer: President, CEO & Director |
PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
| Herb Cross |
officer: Chief Financial Officer |
3061 ZANKER RD, SAN JOSE CA 95134 |
| Scott C. Brun |
director |
C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
| Edwin Jonathan Tucker |
officer: Chief Medical Officer |
C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404 |
| Anna Louise French |
director |
C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004 |
| Kurt Von Emster |
director, 10 percent owner |
601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080 |
| Gary E Rieschel |
10 percent owner |
|
| Qiming U.s. Healthcare Fund Ii, L.p. |
10 percent owner |
350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004 |
| Llp Abingworth |
10 percent owner |
38 JERMYN STREET, LONDON X0 SW1Y 6DN |
| Mark Mcdade |
10 percent owner |
C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040 |
| Qiming U.s. Healthcare Gp Ii, Llc |
10 percent owner |
11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004 |
| Carlyle Group Inc. |
10 percent owner |
C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004 |
Jasper Therapeutics (Jasper Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
JSPR has been successfully added to your